Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis [Yahoo! Finance]
Oculis Holding AG - Ordinary shares (OCS)
Company Research
Source: Yahoo! Finance
FDA Breakthrough Therapy designation for optic neuritis, supported by positive Phase 2 ACUITY data and the launch of the PIONEER registrational program in optic neuropathies. The company is also advancing OCS-01 eye drops toward potential U.S. approval in diabetic macular edema, targeting multi-billion-dollar markets with non-invasive and first-in-class treatment approaches. We'll now examine how FDA breakthrough status for Privosegtor shapes Oculis's investment narrative and long-term ophthalmology pipeline potential. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own Oculis today, you have to believe that its late-stage ophthalmology pipeline can eventually justify a business that currently generates less than CHF1 million in revenue and runs annual losses above CHF100 million. That story now leans even more heavily on two near-term catalysts: Phase 3 DIAMOND da
Show less
Read more
Impact Snapshot
Event Time:
OCS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCS alerts
High impacting Oculis Holding AG - Ordinary shares news events
Weekly update
A roundup of the hottest topics
OCS
News
- Oculis Holding (NasdaqGM:OCS) Valuation Check As Privosegtor Wins FDA Breakthrough Therapy Status [Yahoo! Finance]Yahoo! Finance
- Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare ConferenceGlobeNewswire
- Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis [Yahoo! Finance]Yahoo! Finance
- Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic NeuritisGlobeNewswire
- Oculis (NASDAQ:OCS) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
OCS
Earnings
- 11/10/25 - Beat
OCS
Sec Filings
- 12/9/25 - Form EFFECT
- 12/5/25 - Form POS
- 12/1/25 - Form 424B3
- OCS's page on the SEC website